PORTFOLIO NEWS ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC October 7, 2021 Read More » Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week October 5, 2021 Read More » RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1B Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress September 30, 2021 Read More » Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech September 27, 2021 Read More » Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes September 22, 2021 Read More » ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor September 21, 2021 Read More » NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021 September 16, 2021 Read More » Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates September 8, 2021 Read More » Ribon Therapeutics Announces Key Management Promotions September 1, 2021 Read More » eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies August 25, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC October 7, 2021 Read More »
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week October 5, 2021 Read More »
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1B Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress September 30, 2021 Read More »
Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech September 27, 2021 Read More »
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes September 22, 2021 Read More »
ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor September 21, 2021 Read More »
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021 September 16, 2021 Read More »
Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates September 8, 2021 Read More »
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies August 25, 2021 Read More »
